Does the media prefer CAI or BLFS?

In the previous week, Caris Life Sciences had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for Caris Life Sciences and 4 mentions for BioLife Solutions. Caris Life Sciences' average media sentiment score of 0.85 beat BioLife Solutions' score of 0.77 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STVN or BLFS?

BioLife Solutions has a consensus price target of $31.38, suggesting a potential downside of 10.73%. Given BioLife Solutions' higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 BioLife Solutions 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.18

Does the media refer more to STVN or BLFS?

In the previous week, Stevanato Group had 10 more articles in the media than BioLife Solutions. MarketBeat recorded 14 mentions for Stevanato Group and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Stevanato Group's score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLFS or SHC?

In the previous week, Sotera Health had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Sotera Health and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Sotera Health's score of 0.69 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sotera Health 5 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLFS or ADPT?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 4 mentions for BioLife Solutions. Adaptive Biotechnologies' average media sentiment score of 0.85 beat BioLife Solutions' score of 0.77 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLFS or ALMR?

In the previous week, Alamar Biosciences had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Alamar Biosciences and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Alamar Biosciences' score of 0.57 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioLife Solutions (BLFS) Competitors

$35.15 -0.08 (-0.24%)

As of 01:47 PM Eastern

Compare

BLFS vs. CAI, STVN, SHC, ADPT, and ALMR

Should you buy BioLife Solutions stock or one of its competitors? BioLife Solutions's main competitors and comparable companies include Caris Life Sciences (CAI), Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), and Alamar Biosciences (ALMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does BioLife Solutions compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

BioLife Solutions has a net margin of 53.29% compared to Caris Life Sciences' net margin of 10.62%. Caris Life Sciences' return on equity of 18.77% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
BioLife Solutions	53.29%	2.70%	2.49%

Caris Life Sciences currently has a consensus price target of $26.33, indicating a potential upside of 21.16%. BioLife Solutions has a consensus price target of $31.38, indicating a potential downside of 10.73%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Caris Life Sciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

BioLife Solutions has lower revenue, but higher earnings than Caris Life Sciences. BioLife Solutions is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	17.60	-$68.09M	$0.36	60.37
BioLife Solutions	$96.21M	17.85	-$4.59M	$1.16	30.30

93.2% of BioLife Solutions shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

In the previous week, Caris Life Sciences had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for Caris Life Sciences and 4 mentions for BioLife Solutions. Caris Life Sciences' average media sentiment score of 0.85 beat BioLife Solutions' score of 0.77 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caris Life Sciences beats BioLife Solutions on 10 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Stevanato Group has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.80	€158.21M	€0.56	37.97
BioLife Solutions	$96.21M	17.85	-$4.59M	$1.16	30.30

BioLife Solutions has a net margin of 53.29% compared to Stevanato Group's net margin of 10.99%. Stevanato Group's return on equity of 10.43% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
BioLife Solutions	53.29%	2.70%	2.49%

Stevanato Group has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

In the previous week, Stevanato Group had 10 more articles in the media than BioLife Solutions. MarketBeat recorded 14 mentions for Stevanato Group and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Stevanato Group's score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a consensus price target of $31.38, suggesting a potential downside of 10.73%. Given BioLife Solutions' higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

93.2% of BioLife Solutions shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Stevanato Group beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Sotera Health?

BioLife Solutions (NASDAQ:BLFS) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

BioLife Solutions has a net margin of 53.29% compared to Sotera Health's net margin of 13.44%. Sotera Health's return on equity of 40.12% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Sotera Health	13.44%	40.12%	7.55%

Sotera Health has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	17.85	-$4.59M	$1.16	30.30
Sotera Health	$1.16B	4.64	$77.94M	$0.57	33.18

In the previous week, Sotera Health had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Sotera Health and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Sotera Health's score of 0.69 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	5 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions presently has a consensus target price of $31.38, suggesting a potential downside of 10.73%. Sotera Health has a consensus target price of $21.50, suggesting a potential upside of 13.67%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Sotera Health is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 15.4% of Sotera Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioLife Solutions has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Summary

Sotera Health beats BioLife Solutions on 10 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Adaptive Biotechnologies?

BioLife Solutions (NASDAQ:BLFS) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

BioLife Solutions has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	17.85	-$4.59M	$1.16	30.30
Adaptive Biotechnologies	$276.98M	14.31	-$59.50M	-$0.41	N/A

BioLife Solutions has a net margin of 53.29% compared to Adaptive Biotechnologies' net margin of -20.73%. BioLife Solutions' return on equity of 2.70% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

BioLife Solutions presently has a consensus target price of $31.38, suggesting a potential downside of 10.73%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 1.70%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 4 mentions for BioLife Solutions. Adaptive Biotechnologies' average media sentiment score of 0.85 beat BioLife Solutions' score of 0.77 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adaptive Biotechnologies beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Alamar Biosciences?

BioLife Solutions (NASDAQ:BLFS) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

BioLife Solutions has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	17.85	-$4.59M	$1.16	30.30
Alamar Biosciences	$74.21M	30.74	-$29.82M	-$1.74	N/A

BioLife Solutions presently has a consensus price target of $31.38, indicating a potential downside of 10.73%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential downside of 3.28%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Alamar Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

BioLife Solutions has a net margin of 53.29% compared to Alamar Biosciences' net margin of 0.00%. BioLife Solutions' return on equity of 2.70% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Alamar Biosciences	N/A	N/A	N/A

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Alamar Biosciences had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Alamar Biosciences and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Alamar Biosciences' score of 0.57 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLife Solutions beats Alamar Biosciences on 11 of the 16 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLFS vs. The Competition

Export

Metric	BioLife Solutions	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.71B	$9.47B	$6.98B	$13.02B
Dividend Yield	N/A	1.46%	2.58%	10.72%
P/E Ratio	30.23	60.40	269.27	25.25
Price / Sales	17.85	105.59	597.31	101.05
Price / Cash	152.72	26.03	70.53	50.75
Price / Book	4.09	37.99	13.07	6.33
Net Income	-$4.59M	$56.66B	$3.45B	$347.81M
7 Day Performance	1.40%	0.21%	0.74%	0.90%
1 Month Performance	22.67%	1.47%	1.40%	0.89%
1 Year Performance	38.81%	19.33%	67.03%	20.36%

BioLife Solutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLFS BioLife Solutions	3.0806 of 5 stars	$35.15 -0.2%	$31.38 -10.7%	+37.2%	$1.71B	$96.21M	30.23	440	Short Interest Increase
CAI Caris Life Sciences	4.2262 of 5 stars	$23.57 +0.7%	$26.33 +11.7%	N/A	$6.66B	$348.89M	65.42	1,846
STVN Stevanato Group	3.5743 of 5 stars	€20.72 +0.7%	N/A	-3.5%	€6.32B	€1.34B	37.27	6,010	Positive News
SHC Sotera Health	4.0995 of 5 stars	$19.00 +0.1%	$21.50 +13.2%	+21.0%	$5.41B	$1.16B	33.31	3,000	Positive News Analyst Upgrade Insider Trade
ADPT Adaptive Biotechnologies	1.6623 of 5 stars	$25.82 +1.5%	$24.42 -5.4%	+88.2%	$4.12B	$276.98M	N/A	790

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLFS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Competitors

BLFS vs. CAI, STVN, SHC, ADPT, and ALMR

How does BioLife Solutions compare to Caris Life Sciences?

Summary

How does BioLife Solutions compare to Stevanato Group?

Summary

How does BioLife Solutions compare to Sotera Health?

Summary

How does BioLife Solutions compare to Adaptive Biotechnologies?

Summary

How does BioLife Solutions compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Competitors

BLFS vs. CAI, STVN, SHC, ADPT, and ALMR

How does BioLife Solutions compare to Caris Life Sciences?

Is CAI or BLFS more profitable?

Do analysts recommend CAI or BLFS?

Which has better earnings and valuation, CAI or BLFS?

Do insiders and institutionals have more ownership in CAI or BLFS?

Which has more risk & volatility, CAI or BLFS?

Does the media prefer CAI or BLFS?

Summary

How does BioLife Solutions compare to Stevanato Group?

Which has better valuation & earnings, STVN or BLFS?

Is STVN or BLFS more profitable?

Which has more volatility and risk, STVN or BLFS?

Does the media refer more to STVN or BLFS?

Do analysts prefer STVN or BLFS?

Do institutionals and insiders hold more shares of STVN or BLFS?

Summary

How does BioLife Solutions compare to Sotera Health?

Is BLFS or SHC more profitable?

Which has better earnings & valuation, BLFS or SHC?

Does the media favor BLFS or SHC?

Do analysts prefer BLFS or SHC?

Do insiders & institutionals believe in BLFS or SHC?

Which has more volatility & risk, BLFS or SHC?

Summary

How does BioLife Solutions compare to Adaptive Biotechnologies?

Which has better valuation and earnings, BLFS or ADPT?

Is BLFS or ADPT more profitable?

Which has more volatility & risk, BLFS or ADPT?

Do analysts recommend BLFS or ADPT?

Do institutionals and insiders hold more shares of BLFS or ADPT?

Does the media favor BLFS or ADPT?

Summary

How does BioLife Solutions compare to Alamar Biosciences?

Which has preferable earnings and valuation, BLFS or ALMR?

Do analysts prefer BLFS or ALMR?

Is BLFS or ALMR more profitable?

Do institutionals & insiders believe in BLFS or ALMR?

Does the media refer more to BLFS or ALMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools